+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Asia Pacific Healthcare Bioconvergence Market Size, Share & Industry Trends Analysis Report By Application, By Country and Growth Forecast, 2022 - 2028

  • PDF Icon

    Report

  • 59 Pages
  • December 2022
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5723491
The Asia Pacific Healthcare Bioconvergence Market should witness market growth of 7.4% CAGR during the forecast period (2022-2028).

The examination of nature and its mechanics, models, and their application to the process of the invention is exactly what the Bioconvergence technique entails. This strategy has been gaining ground in the sciences, particularly the life sciences and medical innovation, and for a good cause.

It enables innovators to not only produce better goods and have a genuine impact but also to gain access to more and better capital, which facilitates the creation of these superior products' businesses and their commercialization. The aim to offer consumers better healthcare goods and services led to this amazing development in biosciences.

The healthcare system has undergone significant modifications and revisions recently in an effort to offer the world's population more affordable and efficient medical care. Researchers from all around the world have been examining how to use and mimic nature to treat the majority of the diseases that plague the global populace.

China's population is aging at one of the fastest rates in the world. Due to rising life expectancy and falling birth rates, 28% of China's population is expected to be over 60 by 2040. For public health and socioeconomic development, this profound demographic shift creates a number of new challenges and opportunities. Of particular importance is the creation of an integrated system that meets the social and health needs of older people while ensuring that everyone has access to healthcare, regardless of location.

The China market dominated the Asia Pacific Engineered Living MaterialsMarket by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $808.3 million by 2028. The Japan market is estimated to grow a CAGR of 8.1% during (2022-2028). Additionally, The India market would display a CAGR of 9.4% during (2022-2028).

Based on Application, the market is segmented into Drug Discovery, Precision Medicine, Regenerative Medicine, Diagnostic & Biological Sensors, Bioelectronics, Nanorobotics for Drug Delivery, Engineered Living Materials, and Optogenetics. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BiomX, Inc., Singota Solutions, Anima Biotech Inc., Ginkgo Bioworks Holdings, Inc., SetPoint Medical Corporation, Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences), and BICO Group AB (publ).

Scope of the Study

By Application

  • Drug Discovery
  • Precision Medicine
  • Regenerative Medicine
  • Diagnostic & Biological Sensors
  • Bioelectronics
  • Nanorobotics for Drug Delivery
  • Engineered Living Materials
  • Optogenetics

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

  • BiomX, Inc.
  • Singota Solutions
  • Anima Biotech Inc.
  • Ginkgo Bioworks Holdings, Inc.
  • SetPoint Medical Corporation
  • Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences)
  • BICO Group AB (publ)

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Healthcare Bioconvergence Market, by Application
1.4.2 Asia Pacific Healthcare Bioconvergence Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Asia Pacific Healthcare Bioconvergence Market by Application
3.1 Asia Pacific Drug Discovery Market by Country
3.2 Asia Pacific Precision Medicine Market by Country
3.3 Asia Pacific Regenerative Medicine Market by Country
3.4 Asia Pacific Diagnostic & Biological Sensors Market by Country
3.5 Asia Pacific Bioelectronics Market by Country
3.6 Asia Pacific Nanorobotics for Drug Delivery Market by Country
3.7 Asia Pacific Engineered Living Materials Market by Country
3.8 Asia Pacific Optogenetics Market by Country

Chapter 4. Asia Pacific Healthcare Bioconvergence Market by Country
4.1 China Healthcare Bioconvergence Market
4.1.1 China Healthcare Bioconvergence Market by Application
4.2 Japan Healthcare Bioconvergence Market
4.2.1 Japan Healthcare Bioconvergence Market by Application
4.3 India Healthcare Bioconvergence Market
4.3.1 India Healthcare Bioconvergence Market by Application
4.4 South Korea Healthcare Bioconvergence Market
4.4.1 South Korea Healthcare Bioconvergence Market by Application
4.5 Singapore Healthcare Bioconvergence Market
4.5.1 Singapore Healthcare Bioconvergence Market by Application
4.6 Malaysia Healthcare Bioconvergence Market
4.6.1 Malaysia Healthcare Bioconvergence Market by Application
4.7 Rest of Asia Pacific Healthcare Bioconvergence Market
4.7.1 Rest of Asia Pacific Healthcare Bioconvergence Market by Application

Chapter 5. Company Profiles
5.1 BiomX, Inc.
5.1.1 Company Overview
5.1.2 Research & Development Expenses
5.2 Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences)
5.2.1 Company Overview
5.2.2 Financial Analysis
5.2.3 Segmental and Regional Analysis
5.2.4 Research & Development Expenses
5.3 BICO Group AB (publ)
5.3.1 Company Overview
5.3.2 Financial Analysis
5.3.3 Segmental and Regional Analysis
5.3.4 Recent strategies and developments:
5.3.4.1 Partnerships, Collaborations, and Agreements:
5.3.4.2 Acquisition and Mergers:
5.4 Ginkgo Bioworks Holdings, Inc.
5.4.1 Company Overview
5.4.2 Financial Analysis
5.4.3 Research & Development Expenses
5.4.4 Recent strategies and developments:
5.4.4.1 Partnerships, Collaborations, and Agreements:
5.5 Singota Solutions
5.5.1 Company Overview
5.6 Anima Biotech Inc.
5.6.1 Company Overview
5.7 Setpoint Medical Corporation
5.7.1 Company Overview

Companies Mentioned

  • BiomX, Inc.
  • Singota Solutions
  • Anima Biotech Inc.
  • Ginkgo Bioworks Holdings, Inc.
  • SetPoint Medical Corporation
  • Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences)
  • BICO Group AB (publ)

Methodology

Loading
LOADING...